Given this risk, we thought we'd take a look at whether Dianthus Therapeutics (NASDAQ:DNTH) shareholders should be worried about its cash burn. For the purposes of this article, c ...

Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened ...

Sie haben dennoch Zugriff auf den ungekürzten Text, sofern Sie über einen kostenfreien lifePR-Leser-Zugang verfügen.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received a consensus recommendation of “Buy” from the nine ...

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago. These ...

Reports Q4 revenue $1.33M, consensus $859,700. “We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 ...

Therapeutics announced the appointment of John King as Chief Commercial Officer. King brings more than 25 years of global ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...

NEW YORK and WALTHAM, Mass. - Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a biotech firm, has received FDA clearance for a Phase 2 trial of DNTH103 in Multifocal Motor ...